Login / Signup

Increasing the Interval of Canakinumab Administration Effectively Supports the Remission of Schnitzler's Syndrome.

Vadim Romanovich GorodetskiySvetlana O SaluginaEvgeny S Fedorov
Published in: Case reports in rheumatology (2018)
Schnitzler's syndrome (SchS) is a rare, disabling, autoinflammatory disorder characterized by recurrent urticarial rash and monoclonal IgM gammopathy. Interleukin-1 beta (IL-1β) plays an important role in the pathophysiology of SchS. Only anecdotal reports demonstrate the efficiency and safety of human monoclonal anti-human IL-1β antibody (canakinumab) use in SchS therapy. However, there are no generally accepted recommendations concerning the scheme (or frequency) of canakinumab use for this disease. Here, we report the effective long-term treatment of SchS in a 44-year-old male with a standard canakinumab dose (150 mg) but with an increased 4-month injection interval.
Keyphrases
  • endothelial cells
  • induced pluripotent stem cells
  • pluripotent stem cells
  • case report
  • stem cells
  • emergency department
  • clinical practice
  • rheumatoid arthritis